CXCR4 signaling in health and disease

Immunology Letters

Volumn 177, Issue , 2016, Pages 6-15

  Pozzobon, Tommaso ^a,b   Goldoni, Giacomo ^b   Viola, Antonella ^a,b   Molon, Barbara ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

Chemokine receptors; CXCL12; CXCR4; Immunity; Signaling pathway; WHIM syndrome

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTOME;

B LYMPHOCYTE; BONE MARROW; CXCR4 GENE; DISEASES; HEALTH; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; WART HYPOGAMMAGLOBULINEMIA INFECTION AND MYELOKATHEXIS SYNDROME; ANGIOGENESIS; ANIMAL; GENETICS; IMMUNITY; IMMUNOLOGY; METABOLISM; MORPHOGENESIS; MUTATION; PROTEIN CONFORMATION; VERRUCA VULGARIS;

ANIMALS; CHEMOKINE CXCL12; HUMANS; IMMUNITY; IMMUNOLOGIC DEFICIENCY SYNDROMES; MORPHOGENESIS; MUTATION; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN CONFORMATION; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; TRANSCRIPTOME; WARTS;

EID: 84978820242     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2016.06.006     Document Type: Review

References (109)

1. [1] Yoshimura, T., Matsushima, K., Tanaka, S., Robinson, E.A., Appella, E., Oppenheim, J.J., Leonard, E.J., Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc. Natl. Acad. Sci. U. S. A. 84:24 (1987), 9233–9237.
2. [2] Baggiolini, M., Chemokines and leukocyte traffic. Nature 392:6676 (1998), 565–568.
3. [3] Griffith, J.W., Sokol, C.L., Luster, A.D., Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu. Rev. Immunol. 32 (2014), 659–702.
4. [4] Viola, A., Luster, A.D., Chemokines and their receptors: drug targets in immunity and inflammation. Annu. Rev. Pharmacool. Toxicol. 48 (2008), 171–197.
5. [5] Strieter, R.M., Polverini, P.J., Kunkel, S.L., Arenberg, D.A., Burdick, M.D., Kasper, J., Dzuiba, J., Van Damme, J., Walz, A., Marriott, D., et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 270:45 (1995), 27348–27357.
6. [6] Shim, H., Oishi, S., Fujii, N., Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors. Semin. Cancer Biol. 19:2 (2009), 123–134.
7. [7] Pawig, L., Klasen, C., Weber, C., Bernhagen, J., Noels, H., Diversity and inter-connections in the CXCR4 chemokine receptor/ligand family: molecular perspectives. Front. Immunol., 6, 2015, 429.
8. [8] Bachelerie, F., Graham, G.J., Locati, M., Mantovani, A., Murphy, P.M., Nibbs, R., Rot, A., Sozzani, S., Thelen, M., New nomenclature for atypical chemokine receptors. Nat. Immunol. 15:3 (2014), 207–208.
9. [9] Murdoch, C., Finn, A., Chemokine receptors and their role in inflammation and infectious diseases. Blood 95:10 (2000), 3032–3043.
10. [10] Oldham, W.M., Hamm, H.E., Heterotrimeric G protein activation by G-protein-coupled receptors. Nat. Rev. Mol. Cell Biol. 9:1 (2008), 60–71.
11. [11] Mellado, M., Rodriguez-Frade, J.M., Vila-Coro, A.J., Fernandez, S., Martin de Ana, A., Jones, D.R., Toran, J.L., Martinez, A.C., Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. EMBO J. 20:10 (2001), 2497–2507.
12. [12] Yu, L., Cecil, J., Peng, S.B., Schrementi, J., Kovacevic, S., Paul, D., Su, E.W., Wang, J., Identification and expression of novel isoforms of human stromal cell-derived factor 1. Gene 374 (2006), 174–179.
13. [13] Cinamon, G., Shinder, V., Alon, R., Shear forces promote lymphocyte migration across vascular endothelium bearing apical chemokines. Nat. Immunol. 2:6 (2001), 515–522.
14. [14] Karin, N., The multiple faces of CXCL12 (SDF-1alpha) in the regulation of immunity during health and disease. J. Leukoc. Biol. 88:3 (2010), 463–473.
15. [15] Juarez, J., Bendall, L., SDF-1 and CXCR4 in normal and malignant hematopoiesis. Histol. Histopathol. 19:1 (2004), 299–309.
16. [16] Lataillade, J.J., Domenech, J., Le Bousse-Kerdiles, M.C., Stromal cell-derived factor-1 (SDF-1)\CXCR4 couple plays multiple roles on haematopoietic progenitors at the border between the old cytokine and new chemokine worlds: survival, cell cycling and trafficking. Eur. Cytokine Netw. 15:3 (2004), 177–188.
17. [17] Tachibana, K., Hirota, S., Iizasa, H., Yoshida, H., Kawabata, K., Kataoka, Y., Kitamura, Y., Matsushima, K., Yoshida, N., Nishikawa, S., Kishimoto, T., Nagasawa, T., The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 393:6685 (1998), 591–594.
18. [18] Nagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishikawa, S., Kitamura, Y., Yoshida, N., Kikutani, H., Kishimoto, T., Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382:6592 (1996), 635–638.
19. [19] Busillo, J.M., Benovic, J.L., Regulation of CXCR4 signaling. Biochim. Biophys. Acta 1768:4 (2007), 952–963.
20. [20] De La Luz Sierra, M., Yang, F., Narazaki, M., Salvucci, O., Davis, D., Yarchoan, R., Zhang, H.H., Fales, H., Tosato, G., Differential processing of stromal-derived factor-1alpha and stromal-derived factor-1beta explains functional diversity. Blood 03:7 (2004), 2452–2459.
21. [21] Netelenbos, T., van den Born, J., Kessler, F.L., Zweegman, S., Merle, P.A., van Oostveen, J.W., Zwaginga, J.J., Huijgens, P.C., Drager, A.M., Proteoglycans on bone marrow endothelial cells bind and present SDF-1 towards hematopoietic progenitor cells. Leukemia 17:1 (2003), 175–184.
22. [22] Sadir, R., Imberty, A., Baleux, F., Lortat-Jacob, H., Heparan sulfate/heparin oligosaccharides protect stromal cell-derived factor-1 (SDF-1)/CXCL12 against proteolysis induced by CD26/dipeptidyl peptidase IV. J. Biol. Chem. 279:42 (2004), 43854–43860.
23. [23] Amara, A., Lorthioir, O., Valenzuela, A., Magerus, A., Thelen, M., Montes, M., Virelizier, J.L., Delepierre, M., Baleux, F., Lortat-Jacob, H., Arenzana-Seisdedos, F., Stromal cell-derived factor-1alpha associates with heparan sulfates through the first beta-strand of the chemokine. J. Biol. Chem. 274:34 (1999), 23916–23925.
24. [24] O'Boyle, G., Mellor, P., Kirby, J.A., Ali, S., Anti-inflammatory therapy by intravenous delivery of non-heparan sulfate-binding CXCL12. FASEB J. 23:11 (2009), 3906–3916.
25. [25] Doring, Y., Pawig, L., Weber, C., Noels, H., The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease. Front. Physiol., 5, 2014, 212.
26. [26] Qin, L., Kufareva, I., Holden, L.G., Wang, C., Zheng, Y., Zhao, C., Fenalti, G., Wu, H., Han, G.W., Cherezov, V., Abagyan, R., Stevens, R.C., Handel, T.M., Structural biology. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine. Science 347:6226 (2015), 1117–1122.
27. [27] Loetscher, M., Geiser, T., O'Reilly, T., Zwahlen, R., Baggiolini, M., Moser, B., Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. J. Biol. Chem. 269:1 (1994), 232–237.
28. [28] Rossi, D., Zlotnik, A., The biology of chemokines and their receptors. Annu. Rev. Immunol. 18 (2000), 217–242.
29. [29] Zou, Y.R., Kottmann, A.H., Kuroda, M., Taniuchi, I., Littman, D.R., Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393:6685 (1998), 595–599.
30. [30] Moser, B., Loetscher, P., Lymphocyte traffic control by chemokines. Nat. Immunol. 2:2 (2001), 123–128.
31. [31] Murphy, P.M., The molecular biology of leukocyte chemoattractant receptors. Annu. Rev. Immunol. 12 (1994), 593–633.
32. [32] Cui, L., Qu, H., Xiao, T., Zhao, M., Jolkkonen, J., Zhao, C., Stromal cell-derived factor-1 and its receptor CXCR4 in adult neurogenesis after cerebral ischemia. Restor. Neurol. Neurosci. 31:3 (2013), 239–251.
33. [33] Richardson, B.E., Lehmann, R., Mechanisms guiding primordial germ cell migration: strategies from different organisms. Nat. Rev. Mol. Cell Biol. 11:1 (2010), 37–49.
34. [34] Agarwal, U., Ghalayini, W., Dong, F., Weber, K., Zou, Y.R., Rabbany, S.Y., Rafii, S., Penn, M.S., Role of cardiac myocyte CXCR4 expression in development and left ventricular remodeling after acute myocardial infarction. Circ. Res. 107:5 (2010), 667–676.
35. [35] Sainz, J., Sata, M., CXCR4, a key modulator of vascular progenitor cells. Arterioscler. Thromb. Vasc. Biol. 27:2 (2007), 263–265.
36. [36] Wu, B., Chien, E.Y., Mol, C.D., Fenalti, G., Liu, W., Katritch, V., Abagyan, R., Brooun, A., Wells, P., Bi, F.C., Hamel, D.J., Kuhn, P., Handel, T.M., Cherezov, V., Stevens, R.C., Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330:6007 (2010), 1066–1071.
37. [37] Bachelerie, F., Ben-Baruch, A., Burkhardt, A.M., Combadiere, C., Farber, J.M., Graham, G.J., Horuk, R., Sparre-Ulrich, A.H., Locati, M., Luster, A.D., Mantovani, A., Matsushima, K., Murphy, P.M., Nibbs, R., Nomiyama, H., Power, C.A., Proudfoot, A.E., Rosenkilde, M.M., Rot, A., Sozzani, S., Thelen, M., Yoshie, O., Zlotnik, A., International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol. Rev. 66:1 (2014), 1–79.
38. [38] Moriuchi, M., Moriuchi, H., Turner, W., Fauci, A.S., Cloning and analysis of the promoter region of CXCR4, a coreceptor for HIV-1 entry. J. Immunol. 159:9 (1997), 4322–4329.
39. [39] Moriuchi, M., Moriuchi, H., Margolis, D.M., Fauci, A.S., USF/c-Myc enhances, while Yin-Yang 1 suppresses, the promoter activity of CXCR4, a coreceptor for HIV-1 entry. J. Immunol. 162:10 (1999), 5986–5992.
40. [40] Zhou, H., Tai, H.H., Characterization of recombinant human CXCR4 in insect cells: role of extracellular domains and N-glycosylation in ligand binding. Arch. Biochem. Biophys. 369:2 (1999), 267–276.
41. [41] Marchese, A., Raiborg, C., Santini, F., Keen, J.H., Stenmark, H., Benovic, J.L., The E3 ubiquitin ligase AIP4 mediates ubiquitination and sorting of the G protein-coupled receptor CXCR4. Dev. Cell 5:5 (2003), 709–722.
42. [42] Crump, M.P., Gong, J.H., Loetscher, P., Rajarathnam, K., Amara, A., Arenzana-Seisdedos, F., Virelizier, J.L., Baggiolini, M., Sykes, B.D., Clark-Lewis, I., Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J. 16:23 (1997), 6996–7007.
43. [43] Cheng, M., Huang, K., Zhou, J., Yan, D., Tang, Y.L., Zhao, T.C., Miller, R.J., Kishore, R., Losordo, D.W., Qin, G., A critical role of Src family kinase in SDF-1/CXCR4-mediated bone-marrow progenitor cell recruitment to the ischemic heart. J. Mol. Cell. Cardiol. 81 (2015), 49–53.
44. [44] Chang, F., Steelman, L.S., Shelton, J.G., Lee, J.T., Navolanic, P.M., Blalock, W.L., Franklin, R., McCubrey, J.A., Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int. J. Oncol. 22:3 (2003), 469–480.
45. [45] Ward, S.G., T lymphocytes on the move: chemokines, PI 3-kinase and beyond. Trends Immunol. 27:2 (2006), 80–87.
46. [46] Teicher, B.A., Fricker, S.P., CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin. Cancer Res. 16:11 (2010), 2927–2931.
47. [47] Sun, Y., Cheng, Z., Ma, L., Pei, G., Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J. Biol. Chem. 277:51 (2002), 49212–49219.
48. [48] Rubin, J.B., Chemokine signaling in cancer: one hump or two?. Semin. Cancer Biol. 19:2 (2009), 116–122.
49. [49] Cojoc, M., Peitzsch, C., Trautmann, F., Polishchuk, L., Telegeev, G.D., Dubrovska, A., Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. OncoTargets Ther. 6 (2013), 1347–1361.
50. [50] Krupnick, J.G., Benovic, J.L., The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu. Rev. Pharmacool. Toxicol. 38 (1998), 289–319.
51. [51] Penela, P., Murga, C., Ribas, C., Lafarga, V., Mayor, F. Jr., The complex G protein-coupled receptor kinase 2 (GRK2) interactome unveils new physiopathological targets. Br. J. Pharmacol. 160:4 (2010), 821–832.
52. [52] Cheng, Z.J., Zhao, J., Sun, Y., Hu, W., Wu, Y.L., Cen, B., Wu, G.X., Pei, G., Beta-arrestin differentially regulates the chemokine receptor CXCR4-mediated signaling and receptor internalization, and this implicates multiple interaction sites between beta-arrestin and CXCR4. J. Biol. Chem. 275:4 (2000), 2479–2485.
53. [53] Vila-Coro, A.J., Rodriguez-Frade, J.M., Martin De Ana, A., Moreno-Ortiz, M.C., Martinez, A.C., Mellado, M., The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J. 13:13 (1999), 1699–1710.
54. [54] Gomez-Mouton, C., Lacalle, R.A., Mira, E., Jimenez-Baranda, S., Barber, D.F., Carrera, A.C., Martinez, A.C., Manes, S., Dynamic redistribution of raft domains as an organizing platform for signaling during cell chemotaxis. J. Cell Biol. 164:5 (2004), 759–768.
55. [55] Wysoczynski, M., Reca, R., Ratajczak, J., Kucia, M., Shirvaikar, N., Honczarenko, M., Mills, M., Wanzeck, J., Janowska-Wieczorek, A., Ratajczak, M.Z., Incorporation of CXCR4 into membrane lipid rafts primes homing-related responses of hematopoietic stem/progenitor cells to an SDF-1 gradient. Blood 105:1 (2005), 40–48.
56. [56] Angers, S., Salahpour, A., Bouvier, M., Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annu. Rev. Pharmacol. Toxicol. 42 (2002), 409–435.
57. [57] Levoye, A., Balabanian, K., Baleux, F., Bachelerie, F., Lagane, B., CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 113:24 (2009), 6085–6093.
58. [58] Contento, R.L., Molon, B., Boularan, C., Pozzan, T., Manes, S., Marullo, S., Viola, A., CXCR4-CCR5: a couple modulating T cell functions. Proc. Natl. Acad. Sci. U. S. A. 105:29 (2008), 10101–10106.
59. [59] Sohy, D., Parmentier, M., Springael, J.Y., Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers. J. Biol. Chem. 282:41 (2007), 30062–30069.
60. [60] Kremer, K.N., Kumar, A., Hedin, K.E., G alpha i2 and ZAP-70 mediate RasGRP1 membrane localization and activation of SDF-1-induced T cell functions. J. Immunol. 187:6 (2011), 3177–31785.
61. [61] Libert, F., Parmentier, M., Lefort, A., Dinsart, C., Van Sande, J., Maenhaut, C., Simons, M.J., Dumont, J.E., Vassart, G., Selective amplification and cloning of four new members of the G protein-coupled receptor family. Science 44:4904 (1989), 569–572.
62. [62] Muhlethaler-Mottet, A., Liberman, J., Ascencao, K., Flahaut, M., Balmas Bourloud, K., Yan, P., Jauquier, N., Gross, N., Joseph, J.M., The CXCR4/CXCR7/CXCL12 axis is involved in a secondary but complex control of neuroblastoma metastatic cell homing. PLoS One, 10(5), 2015, e0125616.
63. [63] Decaillot, F.M., Kazmi, M.A., Lin, Y., Ray-Saha, S., Sakmar, T.P., Sachdev, P., CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. J. Biol. Chem. 286:37 (2011), 32188–32197.
64. [64] Sanchez-Martin, L., Sanchez-Mateos, P., Cabanas, C., CXCR7 impact on CXCL12 biology and disease. Trends Mol. Med. 19:1 (2013), 12–22.
65. [65] Molon, B., Gri, G., Bettella, M., Gomez-Mouton, C., Lanzavecchia, A., Martinez, A.C., Manes, S., Viola, A., T cell costimulation by chemokine receptors. Nat. Immunol. 6:5 (2005), 465–471.
66. [66] Sugiyama, T., Kohara, H., Noda, M., Nagasawa, T., Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 25:6 (2006), 977–988.
67. [67] Greenbaum, A., Hsu, Y.M., Day, R.B., Schuettpelz, L.G., Christopher, M.J., Borgerding, J.N., Nagasawa, T., Link, D.C., CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature 495:7440 (2013), 227–230.
68. [68] Christopher, M.J., Liu, F., Hilton, M.J., Long, F., Link, D.C., Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. Blood 114:7 (2009), 1331–1339.
69. [69] Mendez-Ferrer, S., Michurina, T.V., Ferraro, F., Mazloom, A.R., Macarthur, B.D., Lira, S.A., Scadden, D.T., Ma'ayan, A., Enikolopov, G.N., Frenette, P.S., Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 66:7308 (2010), 829–834.
70. [70] Ding, L., Morrison, S.J., Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature 495:7440 (2013), 231–235.
71. [71] Omatsu, Y., Sugiyama, T., Kohara, H., Kondoh, G., Fujii, N., Kohno, K., Nagasawa, T., The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. Immunity 33:3 (2010), 387–399.
72. [72] Chow, A., Lucas, D., Hidalgo, A., Mendez-Ferrer, S., Hashimoto, D., Scheiermann, C., Battista, M., Leboeuf, M., Prophete, C., van Rooijen, N., Tanaka, M., Merad, M., Frenette, P.S., Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J. Exp. Med. 208:2 (2011), 261–271.
73. [73] Nie, Y., Han, Y.C., Zou, Y.R., CXCR4 is required for the quiescence of primitive hematopoietic cells. J. Exp. Med. 205:4 (2008), 777–783.
74. [74] Semerad, C.L., Liu, F., Gregory, A.D., Stumpf, K., Link, D.C., G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. Immunity 17:4 (2002), 413–423.
75. [75] Eash, K.J., Means, J.M., White, D.W., Link, D.C., CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions. Blood 113:19 (2009), 4711–4719.
76. [76] Ma, Q., Jones, D., Borghesani, P.R., Segal, R.A., Nagasawa, T., Kishimoto, T., Bronson, R.T., Springer, T.A., Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 95:16 (1998), 9448–9453.
77. [77] Stein, J.V., Nombela-Arrieta, C., Chemokine control of lymphocyte trafficking: a general overview. Immunology 116:1 (2005), 1–12.
78. [78] Hampton, H.R., Bailey, J., Tomura, M., Brink, R., Chtanova, T., Microbe-dependent lymphatic migration of neutrophils modulates lymphocyte proliferation in lymph nodes. Nat. Commun., 6, 2015, 7139.
79. [79] Kabashima, K., Shiraishi, N., Sugita, K., Mori, T., Onoue, A., Kobayashi, M., Sakabe, J., Yoshiki, R., Tamamura, H., Fujii, N., Inaba, K., Tokura, Y., CXCL12-CXCR4 engagement is required for migration of cutaneous dendritic cells. Am. J. Pathol. 171:4 (2007), 1249–1257.
80. [80] Okada, T., Ngo, V.N., Ekland, E.H., Forster, R., Lipp, M., Littman, D.R., Cyster, J.G., Chemokine requirements for B cell entry to lymph nodes and Peyer's patches. J. Exp. Med. 196:1 (2002), 65–75.
81. [81] Forster, R., Schubel, A., Breitfeld, D., Kremmer, E., Renner-Muller, I., Wolf, E., Lipp, M., CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99:1 (1999), 23–33.
82. [82] Payne, D., Drinkwater, S., Baretto, R., Duddridge, M., Browning, M.J., Expression of chemokine receptors CXCR4, CXCR5 and CCR7 on B and T lymphocytes from patients with primary antibody deficiency. Clin. Exp. Immunol. 156:2 (2009), 254–262.
83. [83] Nie, Y., Waite, J., Brewer, F., Sunshine, M.J., Littman, D.R., Zou, Y.R., The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. J. Exp. Med. 200:9 (2004), 1145–1156.
84. [84] Allen, C.D., Ansel, K.M., Low, C., Lesley, R., Tamamura, H., Fujii, N., Cyster, J.G., Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat. Immunol. 5:9 (2004), 943–952.
85. [85] Schulz, O., Hammerschmidt, S.I., Moschovakis, G.L., Forster, R., Chemokines and chemokine receptors in lymphoid tissue dynamics. Annu. Rev. Immunol. 34 (2016), 203–242.
86. [86] Hauser, A.E., Kerfoot, S.M., Haberman, A.M., Cellular choreography in the germinal center: new visions from in vivo imaging. Semin. Immunopathol. 32:3 (2010), 239–255.
87. [87] Viola, A., Contento, R.L., Molon, B., T cells and their partners: the chemokine dating agency. Trends Immunol. 27:9 (2006), 421–427.
88. [88] Perez-Martinez, M., Gordon-Alonso, M., Cabrero, J.R., Barrero-Villar, M., Rey, M., Mittelbrunn, M., Lamana, A., Morlino, G., Calabia, C., Yamazaki, H., Shirao, T., Vazquez, J., Gonzalez-Amaro, R., Veiga, E., Sanchez-Madrid, F., F-actin-binding protein drebrin regulates CXCR4 recruitment to the immune synapse. J. Cell Sci. 123:Pt. 7 (2010), 1160–1170.
89. [89] Domanska, U.M., Kruizinga, R.C., Nagengast, W.B., Timmer-Bosscha, H., Huls, G., de Vries, E.G., Walenkamp, A.M., A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur. J. Cancer 49:1 (2013), 219–230.
90. [90] Zhao, H., Guo, L., Zhao, H., Zhao, J., Weng, H., Zhao, B., CXCR4 over-expression and survival in cancer: a system review and meta-analysis. Oncotarget 6:7 (2015), 5022–5040.
91. [91] Yagi, H., Tan, W., Dillenburg-Pilla, P., Armando, S., Amornphimoltham, P., Simaan, M., Weigert, R., Molinolo, A.A., Bouvier, M., Gutkind, J.S., A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. Sci. Signal., 4(191), 2011, ra60.
92. [92] Feng, Y., Broder, C.C., Kennedy, P.E., Berger, E.A., HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:5263 (1996), 872–877.
93. [93] Donzella, G.A., Schols, D., Lin, S.W., Este, J.A., Nagashima, K.A., Maddon, P.J., Allaway, G.P., Sakmar, T.P., Henson, G., De Clercq, E., Moore, J.P., AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 4:1 (1998), 72–77.
94. [94] Gorlin, R.J., Gelb, B., Diaz, G.A., Lofsness, K.G., Pittelkow, M.R., Fenyk, J.R. Jr., WHIM syndrome, an autosomal dominant disorder: clinical, hematological, and molecular studies. Am. J. Med. Genet. 91:5 (2000), 368–376.
95. [95] Zuelzer, W.W., Myelokathexis—a new form of chronic granulocytopenia. report of a case. N. Engl. J. Med. 270 (1964), 699–704.
96. [96] Hernandez, P.A., Gorlin, R.J., Lukens, J.N., Taniuchi, S., Bohinjec, J., Francois, F., Klotman, M.E., Diaz, G.A., Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat. Genet. 34:1 (2003), 70–74.
97. [97] Liu, Q., Pan, C., Lopez, L., Gao, J., Velez, D., Anaya-O'Brien, S., Ulrick, J., Littel, P., Corns, J.S., Ellenburg, D.T., Malech, H.L., Murphy, P.M., McDermott, D.H., WHIM syndrome caused by waldenstrom's macroglobulinemia-associated mutation CXCR4 (L329fs). J. Clin. Immunol. 36:4 (2016), 397–405.
98. [98] Lagane, B., Chow, K.Y., Balabanian, K., Levoye, A., Harriague, J., Planchenault, T., Baleux, F., Gunera-Saad, N., Arenzana-Seisdedos, F., Bachelerie, F., CXCR4 dimerization and beta-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome. Blood 112:1 (2008), 34–44.
99. [99] Gomez-Mouton, C., Fischer, T., Peregil, R.M., Jimenez-Baranda, S., Stossel, T.P., Nakamura, F., Manes, S., Filamin A interaction with the CXCR4 third intracellular loop regulates endocytosis and signaling of WT and WHIM-like receptors. Blood 125:7 (2015), 1116–1125.
100. [100] McDermott, D.H., Gao, J.L., Liu, Q., Siwicki, M., Martens, C., Jacobs, P., Velez, D., Yim, E., Bryke, C.R., Hsu, N., Dai, Z., Marquesen, M.M., Stregevsky, E., Kwatemaa, N., Theobald, N., Long Priel, D.A., Pittaluga, S., Raffeld, M.A., Calvo, K.R., Maric, I., Desmond, R., Holmes, K.L., Kuhns, D.B., Balabanian, K., Bachelerie, F., Porcella, S.F., Malech, H.L., Murphy, P.M., Chromothriptic cure of WHIM syndrome. Cell 160:4 (2015), 686–699.
101. [101] Balabanian, K., Levoye, A., Klemm, L., Lagane, B., Hermine, O., Harriague, J., Baleux, F., Arenzana-Seisdedos, F., Bachelerie, F., Leukocyte analysis from WHIM syndrome patients reveals a pivotal role for GRK3 in CXCR4 signaling. J. Clin. Invest. 118:3 (2008), 1074–1084.
102. [102] Kawai, T., Choi, U., Cardwell, L., DeRavin, S.S., Naumann, N., Whiting-Theobald, N.L., Linton, G.F., Moon, J., Murphy, P.M., Malech, H.L., WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4. Blood 109:1 (2007), 78–84.
103. [103] Walters, K.B., Green, J.M., Surfus, J.C., Yoo, S.K., Huttenlocher, A., Live imaging of neutrophil motility in a zebrafish model of WHIM syndrome. Blood 116:15 (2010), 2803–2811.
104. [104] Balabanian, K., Brotin, E., Biajoux, V., Bouchet-Delbos, L., Lainey, E., Fenneteau, O., Bonnet, D., Fiette, L., Emilie, D., Bachelerie, F., Proper desensitization of CXCR4 is required for lymphocyte development and peripheral compartmentalization in mice. Blood 119:24 (2012), 5722–5730.
105. [105] Mc Guire, P.J., Cunningham-Rundles, C., Ochs, H., Diaz, G.A., Oligoclonality, impaired class switch and B-cell memory responses in WHIM syndrome. Clin. Immunol. 135:3 (2010), 412–421.
106. [106] Kallikourdis, M., Trovato, A.E., Anselmi, F., Sarukhan, A., Roselli, G., Tassone, L., Badolato, R., Viola, A., The CXCR4 mutations in WHIM syndrome impair the stability of the T-cell immunologic synapse. Blood 122:5 (2013), 666–673.
107. [107] Handisurya, A., Schellenbacher, C., Reininger, B., Koszik, F., Vyhnanek, P., Heitger, A., Kirnbauer, R., Forster-Waldl, E., A quadrivalent HPV vaccine induces humoral and cellular immune responses in WHIM immunodeficiency syndrome. Vaccine 28:30 (2010), 4837–4841.
108. [108] McDermott, D.H., Liu, Q., Ulrick, J., Kwatemaa, N., Anaya-O'Brien, S., Penzak, S.R., Filho, J.O., Priel, D.A., Kelly, C., Garofalo, M., Littel, P., Marquesen, M.M., Hilligoss, D., Decastro, R., Fleisher, T.A., Kuhns, D.B., Malech, H.L., Murphy, P.M., The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood 118:18 (2011), 4957–4962.
109. [109] Devi, S., Wang, Y., Chew, W.K., Lima, R., Noelia, A.-G., Mattar, C.N., Chong, S.Z., Schlitzer, A., Bakocevic, N., Chew, S., Keeble, J.L., Goh, C.C., Li, J.L., Evrard, M., Malleret, B., Larbi, A., Renia, L., Haniffa, M., Tan, S.M., Chan, J.K., Balabanian, K., Nagasawa, T., Bachelerie, F., Hidalgo, A., Ginhoux, F., Kubes, P., Ng, L.G., Neutrophil mobilization via plerixafor-mediated CXCR4 inhibition arises from lung demargination and blockade of neutrophil homing to the bone marrow. J. Exp. Med. 210:11 (2013), 2321–2336.